Business & Economy
Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.
Business & Economy 
Story intelligence
Coverage Checking
Views New Be the first to read
Brief read Under 1 min brief 21 words
AI Summary
Lilly is testing an experimental amylin drug that could help people lose weight and manage diabetes, similar to a GLP‑1 medication.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Business & Economy
Continue reading recent Business & Economy coverage
- Google Wants Hollywood to Stop Being So Afraid of TechnologyContinue reading
- Fed’s preferred gauge showed core inflation at 3.0% in August, much lighter than expectedContinue reading
- ‘We lived within our means’: I earned $30,000 as a pastor and still retired comfortably. Why don’t you tell people that?Continue reading
- Wilbur Ross says New York’s pied-à-terre tax targets people who ‘can’t retaliate at the ballot box’Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow